3. Riddle, C. M., Bolli, G. C. Ziemen, M. et al.; EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 37, 10: 2755–2762, 2014.
4. Comparison of a new formulation of insulin glargine with lantus in patients with type 2 diabetes on basal insulin with oral antidiabetic therapy (EDITION II). NCT01499095. ClinicalTrials.gov (online: https://clinicaltrials.gov/ct2/show/NCT01499095?term=NCT01499095&draw=2&rank=1) [cit. 3. 1. 2023]
5. Yki-Järvinen, H., Bergenstal, R. M., Bolli, G. B. et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab 17, 15: 1142–1149, 2015.
6. Bolli, G. B., Riddle, M. C., Bergenstal, R. M. et al.; EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 17, 4: 386–394, 2015.
7. Comparison of a new formulation of insulin glargine with Lantus in patients with type 2 diabetes on non-insulin antidiabetic therapy. NCT01676220. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT01676220?term=EDITION+glargine&draw=2&rank=3) [cit. 3. 1. 2023]
8. Comparison of a new formulation of insulin glargine with Lantus in patients with type 1 diabetes mellitus (EDITION IV). NCT01683266. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT01683266?term=EDITION+glargine&draw=2&rank=7) [cit. 3. 1. 2023]
9. Home, P. D., Bergenstal, R. M., Bolli, G. B. et al. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab 20, 1: 121–128, 2018.
10. Comparison of the safety and efficacy of HOE901-U300 with Lantus in older patients with type 2 diabetes insufficiently controlled on their current antidiabetic medications (SENIOR). NCT02320721. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT02320721?term=SENIOR+Glargine&draw=2&rank=1) [cit. 3. 1. 2023]
11. Ritzel, R., Harris, S. B., Baron, H. et al. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 Units/mL versus 100 Units/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care 41, 8: 1672–1680, 2018.
12. Danne, T., Tamborlane, W. V., Malievsky, O. A. et al. Efficacy and safety of insulin glargine 300 Units/mL (Gla-300) versus insulin glargine 100 Units/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes: Results od the EDITION JUNIOR randomized controlled trial. Diabetes Care 43, 7: 1512–1519, 2020.
13. Comparison of the safety and efficacy of HOE901-U300 with Lantus in children and adolescents with type 1 diabetes mellitus (EDITION JUNIOR). NCT02735044. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT02735044?term=EDITION+JUNIOR&draw=2&rank=1) [cit. 3. 1. 2023]
14. Meneghini, L., Sullivan, S. D., Oster, G. A pragmatic randomised clinical trial of insulin glargine 300 U/mL vs firt-generation basal insulin analogues in insulin-naive patients with type 2 diabetes: ACHIEVE Control. Diabetes Obes Metab 22, 11: 2004–2012, 2020.
15. Freemantle, N., Mauricio, D., Giaccari, A. et al, REACH and REGAIN investigators. Real-world outcomes of treatment with insulin glargine 300 U/ml versus standard-of-care in people with uncotrolled type 2 diabetes mellitus. Curr Med Res Opin 36, 4: 571–581, 2020.
16. A real world trial to determine efficacy and health outomes of Toujeo compared to standard of care basal insulins in insulin naive patients initiating insulin (Reach-Control). NCT02967224. ClinicalTrials.gov (online: https://clinicaltrials.gov/ct2/show/NCT02967224) [cit. 3. 1. 2023]
17. A real world trial to determine efficacy and health outomes of Toujeo compared to standard of care basal insulins in patients already using basal insulin (REGAIN CONTROL). NCT02967211. ClinicalTrials.gov (online: https://clinicaltrials.gov/ct2/show/NCT02967211) [cit. 3. 1. 2023]
18. Zhou, F. L., Ye, F., Gupta, V. et al. Lower Risk of Hypoglycemia after Switch to Insulin Glargine 300 U/ML (Gla-300) Vs Other Basal Insulins in Patients with Type 2 Diabetes (T2D) on Basal Insulin in Real-World Clinical Settings (DELIVER 2 study), Poster presentation LB SUN 81, Endocrine Society 2017 Annual Meeting, Orlando, FL, U.S. (online: https://plan.core-apps.com/tristar_endo17/abstract/3bd82d7fc3f20d086b212c74bc2ea6b7)
19. DELIVER 2. Data z reálné klinické praxe. Kazuistiky v diabetologii 15, 2: 60, 2017.
20. Meneghini, L., Zhou, F. L., Bosnyak, Z. et al. Hypoglycemia risk associated with basal insulin use in type 2 diabetes (T2DM): the LIGHTNING study. Abstrakt z: ATTD, 14.–17. 2. 2018, Vienna, Austria.
21. Studie LIGHTNING – glargin 300 U/ml v reálné praxi prokazuje nízké riziko hypoglykemií. Kazuistiky v diabetologii 16, 1: 22, 2018.
22. Vízner, K. První přímé srovnání dlouhodobě působících inzulínových analog 2. generace. Kazuistiky v diabetologii 16, 3: 12, 2018.
23. Cheng, A., Rosenstock, J., Ritzel, R. et al. Similar glycemic control and less or comparable hypoglycemia with insulin glargine 300 U/mL (Gla-300) vs degludec 100 U/mL (IDeg-100) in insulin-naïve adults with T2DM on antihyperglycemic drugs ± GLP-1 RAs: the BRIGHT randomized study. Diabetes 67, Supl. 1, 2018.
24. Bolli, G. B., Cheng, A., Bosnyak, Z. et al. Lower hypoglycemia rates with insulin glargine 300 U/mL (Gla-300) vs. insulin degludec 100 U/mL (IDeg-100) in insulin-naïve adults with T2DM on oral antihyperglycemic therapy ± GLP-1RA – The BRIGHT randomized study. Abstrakt z: General poster sessions, 78th Scientific Sessions ADA, 22.–26. 6. 2018, Orlando, USA.
25. Studie InRange. Přímé srovnání inzulínu glargin 300 U/ml a degludek 100 U/ml. Kazuistiky v diabetologii 20, 2: 51–52, 2022.
26. Comparison of glucose values and variability between Toujeo and Tresiba during continuous glucose monitoring in type 1 diabetes patients (inRange). NCT04075513. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT04075513?term=NCT04075513&draw=2&rank=1) [cit. 18. 5. 2022]
27. Battelino, T., Danne, T., Edelman, S. V. et al. Time in Range using insulin glargine 300 U/mL versus insulin degludec 100 U/mL in type 1 diabetes: head-to-head randomised controlled InRange trail. Abstract, ATTD 2022.
28. Meneghini, L., Sullivan, S. D., Oster, G. A pragmatic randomised clinical trial of insulin glargine 300 U/mL vs firt-generation basal insulin analogues in insulin-naive patients with type 2 diabetes: ACHIEVE Control. Diabetes Obes Metab 22, 11: 2004–2012, 2020.
29. A real world trial to determine efficacy and health outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM). NCT02451137. ClinicalTrials.gov (online: https://www.clinicaltrials.gov/ct2/show/NCT02451137?term=nct02451137&draw=2&rank=1) [cit. 4. 1. 2023]
30. Anderson, J., Meneghini, L., Hinnen, D. et al. Target attainment in insulin-naive patients at high risk for hypoglycemia: results ACHIEVE Control. J Diabetes Complications 35, 4: 107831, 2020.